Citigroup reaffirmed a neutral rating on Sanofi stock.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reaffirmed a neutral rating on Sanofi stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sanofi
French pharmaceutical company
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup restated a buy rating on the stock of Stora Enso.
- Citigroup reiterated a neutral rating on Olin stock.
- Citigroup reissued a positive rating on Cameco shares.
- Citigroup reaffirmed a neutral rating on AvePoint, and insider transactions involving the company were disclosed to the SEC.
- Citigroup issued a neutral rating on Genpact shares, while TD Cowen reduced its price target and set a buy rating.